Shengjie Kang Completes RMB 60 Million Series A Funding to Develop China's First Endoluminal Tumor Cryoablation System

VCBeat (WeChat ID: vcbeat) has learned that Sheng Jiekang, a Chinese company specializing in innovative devices and consumables for the minimally invasive field, recently completed a RMB 60 million Series A financing round. The round was led by Yuansheng Venture Capital, with participation from Fudan Hangzhou Bay Innovation and Entrepreneurship Fund and other investors.

Ningbo Shengjiekang Biotechnology Co., Ltd. (hereinafter referred to as “Shengjiekang”) was established in 2011 and is an innovative company dedicated to the research and development, production, and sales of high-value consumables in the field of endoscopic minimally invasive procedures.

The company focuses on the fields of tumor cryoablation and endoscopic/laparoscopic minimally invasive procedures, with single-port laparoscopic surgery as its entry point and tumor cryotherapy and natural orifice surgery as its key areas. It has developed a portfolio of products with “exclusive” characteristics and filed 41 patents.

Shengjiekang’s core products include multi-channel laparoscopic access systems, multi-degree-of-freedom surgical instruments, tumor cryoablation systems, anti-gastroesophageal reflux systems, and pulmonary nodule localization needles. These innovations drive the improvement and advancement of minimally invasive surgical technologies, while progressively enabling comprehensive, specialty-specific solutions for medical consumables.

Shengjie Kang is the earliest company in China to develop cryoablation technology for intraluminal tumors, with its core product “Natural Orifice Tumor Cryoablation System“Tumors can be treated non-invasively through natural body orifices such as the esophagus, stomach, colorectum, bladder, and cervix. This product has been granted priority review status under the National Medical Device Priority Review Pathway.”

Cryotechnology has been utilized for tumor ablation for several decades. Its primary mechanism involves the cryoablation and inactivation of pathological tissues through profound hypothermia or alternating cold–warm cycles, thereby destroying diseased cells at the target site while preserving the structural integrity and function of human organs. This approach reduces tumor recurrence rates and minimizes the need for chemotherapy.

Currently, all globally approved tumor cryoablation systems are indicated for solid tumors, including lesions in the kidney, lung, and breast. The efficacy of cryotherapy based on freezing principles has gained clinical recognition.Shengjiekang’s transnatural orifice tumor cryoablation system is poised to become the first cryoablation product specifically designed for endoluminal tumors.

Another core product of the company “Multi-Channel Laparoscopic Access System”, and has already obtained the medical device registration certificate. This product can convert conventional multi-port laparoscopic minimally invasive surgery into single-port laparoscopic minimally invasive surgery. Currently, in Europe and other regions, single-port surgery has become the gold standard for procedures such as cholecystectomy.

In China, single-port surgery has been applied to some extent in gynecology, urology, general surgery, and thoracic surgery, but it has not yet become a recommended surgical approach as it has abroad. As domestic surgeons continue to learn from and catch up with their international counterparts, there remains significant potential for the broader adoption of single-port surgical techniques.

The Company's“Lung Nodule Localization Needle”is expected to obtain the product registration certificate in 2018,This product is currently the only one on the market suitable for lung nodule localization., featuring puncture localization, flexible fixation, and depth markers. The incidence of pulmonary nodules has been rising in recent years, and this product will fill a gap in the domestic market upon its launch.

Furthermore, the company has also developed innovative products such as an “Anti-Gastroesophageal Reflux System” and a novel “Ureteral Dilation Catheter,” which are scheduled to be gradually launched in the future.

Yuansheng Ventures is an investment firm focused on the early and growth stages of the healthcare sector. Based in bioBAY, it extends its reach across China and globally. The firm currently manages approximately RMB 2 billion in assets and has completed investments in nearly 50 high-quality projects, primarily spanning new drug development, innovative medical devices, and precision medicine. It has delivered substantial investment returns and has been repeatedly recognized as one of the Top 10 Venture Capital Funds in China’s healthcare sector and one of the Most Active Healthcare Investment Institutions in China.

YuanSheng Venture Capital brings together a team of seasoned professional investors and world-class scientific advisors, with extensive experience in entrepreneurship, venture capital, and corporate operations in the biopharmaceutical industry and beyond. Leveraging its focused strategy and abundant industry resources, YuanSheng Venture Capital is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Regarding this round of financing, the team stated that in medical device investment, OrbiMed remains committed to introducing advanced foreign technologies, facilitating the localization of medical devices, and supporting independent innovation by domestic teams.We are optimistic about the application and development of cryogenic technology in oncology and other fields; previously, Yuansheng Venture Capital had already invested in the application of cryogenic technology in the cardiovascular sector.

Yuansheng Venture Capital believes that Shengjie Kang’s professional technical team possesses sustained innovation capabilities, enabling the development of products that better meet clinical needs and address clinical pain points, while striving to provide comprehensive solutions for endoscopic minimally invasive surgical instruments and consumables., we look forward to Shengjie Kang becoming a pioneer and leader in endoluminal tumor cryoablation technology in China.

Fudan Hangzhou Bay Innovation and Entrepreneurship Fund is a venture capital fund professionally managed and operated by Fudan Ningbo Innovation Center Co., Ltd., a subsidiary of Fudan University Ningbo Research Institute. Focusing on biopharmaceuticals, new energy, new materials, intelligent manufacturing, and other sectors, the fund provides angel and venture capital investments to high-quality startup projects intending to establish themselves in the Ningbo Hangzhou Bay New Zone.

This fund, in conjunction with the Fudan Hangzhou Bay Science and Technology Innovation Park, provides integrated entrepreneurial services encompassing space, management, and technical support. It is a specialized angel and venture capital investment fund focused on innovation and entrepreneurship in Ningbo City and Zhejiang Province.

They also believe that Shengjiekang will pioneer new application areas for tumor cryoablation technology in China, becoming a “game-changer” in the treatment of cavity tumors.